Related Experiment Video
Updated: Jun 16, 2025
Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
MIF aggravates experimental autoimmune prostatitis through activation of the NLRP3 inflammasome via the PI3K/AKT
Fei Zhang1, Tong Meng1, Rui Feng2
1Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China; Institute of Urology, Anhui Medical University, Hefei 230022, PR China; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei 230022, PR China.
Abstract:
In our investigation, we investigated the role of macrophage migration inhibitory factor (MIF), a key cytokine, in chronic nonbacterial prostatitis (CNP), an underexplored pathology. Elevated MIF expression was observed in the serum of individuals with chronic prostatitis-like symptoms (CP-LS) as well as in serum and tissue samples from experimental autoimmune prostatitis (EAP) mouse model. Treatment with ISO-1, a specific MIF antagonist, effectively mitigated prostatic inflammation and macrophage infiltration, thereby emphasizing the critical role of MIF in orchestrating immune responses within the prostate microenvironment. Further analyses revealed that MIF stimulates the PI3K/AKT and NLRP3 inflammasome pathways, which are integral to inflammation and cellular immunity. Pharmacological inhibition of the PI3K/AKT pathway by LY294002 substantially reduced prostatic inflammation and macrophage infiltration, potentially by inhibiting NLRP3 inflammasome activation. These findings collectively suggest that MIF is a potential diagnostic marker for CNP and suggest that targeting MIF or its downstream signalling pathways, PI3K/AKT and NLRP3, might represent a novel therapeutic strategy for this condition.
Insights
Macrophage migration inhibitory factor (MIF) drives chronic nonbacterial prostatitis (CNP) by activating key inflammatory pathways. Targeting MIF or its downstream signaling offers a potential new treatment for this condition.
Area of Science:
- Immunology
- Urology
- Molecular Biology
Background:
- Chronic nonbacterial prostatitis (CNP) is an understudied condition.
- Macrophage migration inhibitory factor (MIF) is a key cytokine implicated in inflammatory processes.
Purpose of the Study:
- To investigate the role of MIF in CNP.
- To explore MIF's downstream signaling pathways in prostatitis.
- To evaluate MIF antagonists and pathway inhibitors as potential therapeutic strategies.
Main Methods:
- Measured MIF expression in patients with chronic prostatitis-like symptoms (CP-LS) and in an experimental autoimmune prostatitis (EAP) mouse model.
- Administered a MIF antagonist (ISO-1) and a PI3K/AKT inhibitor (LY294002) in the EAP model.
- Analyzed prostatic inflammation, macrophage infiltration, and activation of PI3K/AKT and NLRP3 inflammasome pathways.
Main Results:
- Elevated MIF levels were found in serum of CP-LS patients and in EAP mouse models.
- MIF antagonism with ISO-1 reduced prostatic inflammation and macrophage infiltration.
- MIF was shown to activate PI3K/AKT and NLRP3 inflammasome pathways, which were inhibited by LY294002, reducing inflammation.
Conclusions:
- MIF plays a critical role in mediating prostate inflammation in CNP.
- MIF is a potential diagnostic biomarker for CNP.
- Targeting MIF or its downstream PI3K/AKT and NLRP3 pathways presents a promising therapeutic avenue for CNP.
